by Sam Tetlow | Apr 16, 2024 | Funding Strategies, Non-Dilutive Funds
In our dynamic world of life sciences, the journey from innovative idea to market success is complex and challenging. Starting in the early 1940’s the KOL has become an instrumental and pivotal aspect to a viable go to market strategy. One crucial aspect of this...
by Sam Tetlow | Mar 7, 2024 | Funding Strategies, Funding Your R&D, Uncategorized
In 2024, the National Institutes of Health (NIH) continues its mission to foster medical and behavioral research through its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Integral to these programs is the budget...
by Sam Tetlow | Mar 5, 2024 | Funding Strategies, Grantsmanship, Non-Dilutive Financing, Uncategorized
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs stand out as critical catalysts in the dynamic technological innovation landscape, encouraging small businesses to engage in research and development with commercial...
by Sam Tetlow | Feb 20, 2024 | Accounting & Reporting, Funding Strategies, Funding Your R&D, Grantsmanship
The Small Business Innovation Research (SBIR) program is essential for scientific and technological advancement, requiring meticulous financial management. Understanding the distinction between allowable and unallowable expenses under this program is crucial for...
by Sam Tetlow | Jul 12, 2022 | Applying for Grant, Featured Post, Funding Strategies, Funding Your R&D, Uncategorized
New technology has led to definitive progress in diagnosing, treating, and analyzing clinical conditions for patients in the United States and beyond. One such development is Software as a Medical Device, the name for software products that have clinical uses but do...
by Sam Tetlow | Aug 27, 2021 | Funding Strategies, Funding Your R&D
NIH_Topics_for_Budget_WaiversDownload Every funding period, NIH announces topics approved for budgets greater than $259,613 for Phase I SBIR/STTR awards, and greater than $1,730,751 for Phase II, presenting a lucrative opportunity for businesses. That being said, NIH...
Recent Comments